Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)

Thomas E. Witzig, Patrick B. Johnston, Betsy R. LaPlant, Paul J. Kurtin, Levi D. Pederson, Dennis F. Moore, Nassim H. Nabbout, Daniel A. Nikcevich, Kendrith M. Rowland, Axel Grothey

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)'. Together they form a unique fingerprint.

Medicine & Life Sciences